Navigator Seminare Publikationen Inhouse eLearning Beratung

home
  Navigator Seminare Publikationen Inhouse eLearning Beratung

GMP-News informieren Sie regelmäßig
über Aktuelles und Trends
aus der GMP Welt.

GMP-News


 

GMP-SUCHE

Eingabe der Schlagworte

Suche im Bereich

 
GMP-News

24. September 2002
 

 
21 CFR 211.198
Complaint Warning Letters im Detail
 

 
Wir haben für Sie die Warning Letters der FDA (01/2001-08/2002) speziell bezüglich der Beanstandungen zum Thema "Complaint Handling" ausgewertet. Diese Auswertung ermöglicht es Ihnen zu erkennen, welche Defizite im Detail angesprochen werden.

Originalzitat Warning Letter

Firma / Datum

"Failure to have written procedures that describe the handling of all written and oral complaints of possible failure of a drug product include a provision for review of the complaint by the quality control unit. In addition, the complaint files reviewed during the inspection did not contain a discussion of the results of the investigations or give a description of the nature of the complaint [21 CFR 211.198(a) & (b)(l)]."

Savant Medical Supply, Inc.;

Forest Park, IL / 09.03.01

"Failure to have adequate complaint procedures established in that instructions concerning FDA post-marketing adverse drug experiences do not describe what needs to be reported or establish timeframes for reporting [21 CFR 211. 198(a)]."

Veterinary Laboratories, Inc.;

Lenexa, KS / 16.04.01

"Failure to establish written procedures that describe the handling of all oral and written complaints regarding a drug product as required by 21 CFR 211.198 (a)."

Grafor Manufacturing, Inc.;

Ponce, PR / 20.04.01

"Additionally, you have failed to establish written operating procedures for drug production and process control steps. For example, for … complaint handling procedures (21 CFR 211.198)."

Farouk Systems, Inc.;

Houston, TX / 01.08.01

"Failure to establish written procedures that describe the handling of all written and oral complaints regarding Oxygen, USP, filled at your facility [21 CFR 211.198(a)]."

Baker's Pharmacy;

Winchester, IL / 17.08.01

"Failure to maintain complaint handling procedures to include provisions for review to determine whether the complaint represents a serious and unexpected adverse drug experience which is required to be reported to FDA [21 CFR 211.198(a)]."

Iso-Tex Diagnostics, Inc.;

Friendswood, Texas / 08.11.01

"Failure to establish written procedures (21 CFR … 211.198) for the following: The handling of written and oral consumer complaints."

Pharmaceutical Distribution Systems;

Montclair, Virginia / 03.01.02

"Failure to establish and follow adequate procedures for handling and investigating complaints regarding product quality. [21 CFR 211.198]."

Medicate Home Care Equipment

Farmington, MO / 12.07.02

"Failure to have written procedures for handling all written and oral complaints regarding your drug products as required by 21 C.F.R. § 211.198."

Furness Medical Inc.

Palatine, Illinois / 25.07.02

"Failure to determine a need for an investigation and failure to conduct investigations into complaints that pertain to released drug products [21 CFR 211.198].

For example, there is no complaint evaluation to determine quality problems nor are the individuals taking these complaints trained to evaluate complaints that may indicate quality problems."

COATS Aloe International, Inc. ;

Garland, Texas / 01.05.01

"There is no documentation of a complaint received regarding released product [21 CFR 211.198(b)]."

American Home Health Care Company;

Sioux City, IA / 27.08.01

"There is no complaint file, nor are appropriate investigations of complaints conducted [21 CFR 211.198].

The lack of adequate control over your repacking operation has led to numerous complaints (Medwatch reports) including: mislabeled drug products; lots with multiple expiration dates; poor blister pack seals; no package insert or the wrong insert; the lack of an Rx legend; and the wrong drug in the unit dose containers. These complaints generated two recalls by your firm in the past year, both of which were undocumented and inadequately handled."

TYA Pharmaceuticals

Tallahassee. FL / 06.08.02

Fazit:

Im Jahr 2001 und den ersten 8 Monaten in 2002 wurden in insgesamt 12 Warning Letters Mängel bezüglich 21 CFR 211.198 (Complaint files) aufgeführt. Die überwiegende Anzahl der Mängel bezieht sich auf das Fehlen schriftlicher Anweisungen über den Umgang mit Beanstandungen (6 von 8 WLs in 2001 und 3 von 4 in 2002).

Weitere Rügen betreffen den Umgang mit Reklamationen selbst wie z.B.:

  • fehlende Dokumentation eingegangener Reklamationen
  • fehlende Auswertung von Reklamationen
  • kein in der Auswertung von Reklamationen geschultes Personal
  • nicht durchgeführte Untersuchungen von Qualitätsmängeln trotz zahlreicher Beanstandungen und Rückrufe

Speziell mit diesem Themenkreis befasst sich unser Seminar EG-GMP-/FDA-gerechte Bearbeitung von Reklamationen und Beanstandungen, das am 29. Oktober 2002 in Mannheim stattfindet.

Autor: Dr. Gerhard Becker, CONCEPT HEIDELBERG